Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06580041CT.gov Precision Care for Major Depressive Disorder | — | Enrolling By Invitation | — | — | — |
NCT06355414CT.gov Psilocybin in Chronic Low Back Pain and Depression | — | Recruiting | — | — | — |
NCT01497548CT.gov Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients | — | Unknown | — | — | — |
NCT00602290CT.gov Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression | — | Completed | — | — | — |
NCT00069927CT.gov Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression | — | Terminated | — | — | — |
NCT00031798CT.gov Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methylphenidate (this asset) | University of California, San Francisco | Approved | BB · 66 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Saredutant | Sanofi | P3 | BBB |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | VA Office of Research and Development | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Methylphenidate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Attention Deficit-Hyperactivity Disorder | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P3 | BB · 70 |
| Alzheimer Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methylphenidate in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methylphenidate-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →